References
- Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: Review and analysis of 115 Cases. Biol Psychiatry 1987; 22: 1004–1020
- Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000; 85: 129–135
- Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sindhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65: 464–470
- Beaujean DJ, Blok HE, Vandenbroucke-Grauls CM, Weersink AJ, Raymakers JA, Verhoef J. Surveillance of nosocomial infections in geriatric patients. J Hosp Infect 1997; 36: 275–284
- Chamorro A, Urra X, Planas A. Infection after acute ischemic stroke: a manifestation of brain-induced immunodepression. Stroke 2007; 38: 1097–1103
- Choi-Kain L, Pope H. “Atypical” neuroleptic malignant syndrome and the spectrum of malignant cerebrotoxic syndromes. Harv Rev Psychiatry 2007; 15: 181–186
- Gurrera R. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999; 156: 169–180
- Guze BH, Baxter L, Jr. Current concepts: Neuroleptic malignant syndrome. New Engl J Med 1985; 313: 163–166
- Kaufmann, CA, Wyatt RJ. Neuroleptic malignant syndrome. 1987. In:. H Meltzer, editor. Psychopharmacology: The third generation of progress. New York: Raven.
- Lazarus A. Should neuroleptic malignant syndrome be treated in a private psychiatric hospital or a general hospital?. Gen Hosp Psychiatry 1990; 12: 245–247
- Lenz A, Franklin G, Cheadle W. Systemic inflammation after trauma. Injury 2007; 38: 1336–1345
- Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142: 1137–1145
- Liam CK, Ong SBY. Neuroleptic malignant syndrome with renal and respiratory complications: a case report. Sing Med J 1990; 31: 182–184
- Muhammed K, Raman P. Simultaneus occurrence of toxic epidermal necrolysis and neuroleptic malignant syndrome. Indian J Dermatol Venereol Leprol 2005; 71: 270–272
- Patel U, Argawal M, Krishnan P, Niranjan S. Neuroleptic malignant syndrome presenting as pulmonary edema and severe bronchorrhea. J. Natl Med Assoc 2002; 94: 279–282
- Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv 1998; 49: 1163–1172
- Reulbach U, Dutsch C, Biermann T, Sperling W, Thuerauf N, Kornhuber J., et al. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care 2007; 11: R4
- Rubin B. Physiology of airway mucus clearance. Respir Care 2002; 47: 761–768
- Sachdev P. Neuroleptic-induced movement disorders: an overview. Psychiatr Clin North Am 2005; 28: 255–274
- Schwacha M, Chaudry I. The cellular basis of post-burn immunosuppression: macrophages and mediators. Int J Mol Med 2002; 10: 239–243
- Sherman CB, Hashimoto F, Davidson EJ. Gas-producing escherichia coli fasciitis in a patient with the neuroleptic malignant syndrome. J Am Med Assoc 1983; 250: 361
- Smith JA, Carter GH. Neuroleptic malignant syndrome with a positive Weil–Felix test. Am J Psychiatry 1984; 141: 609
- Still J, Friedman B, Law E, et al. Neuroleptic malignant syndrome in a burn patient. Burns 1998; 24: 573–575
- Srawn J, Keck P, Caroff S. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164: 870–876
- Teglia MQ, Hopkins TT, Cunha BA. Neuroleptic malignant syndrome and Escherichia coli urosepsis. Heart Lung 1991; 20: 202–205